Apogee Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Apogee Therapeutics, Inc. (APGE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $572.74 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-10
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $572.74M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $268.16M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $216.17M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $43.93M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $572.74M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $268.16M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $216.17M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $43.93M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $57.20M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $39.34K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $61.51M 10-K · filed 2026-03-02 | $61.51K 10-K · filed 2025-03-03 |
| 2024-09-30 | $102.97K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $46.41K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $115.69M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $16.15K 10-K · filed 2025-03-03 | $16.15M 10-K · filed 2024-03-05 |
| 2023-09-30 | $1.32M 10-Q · filed 2023-11-13 |